Tumor suppressor candidate 3 (TUSC3) inhibited tumorigenesis in ovarian cancer, prostate cancer, glioblastoma and pancreatic cancer but enhanced cancer progression in head and neck cancer and CRC (39). This evidence concerns the gene TUSC3 and ovarian carcinoma.